Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: A case report

被引：4

作者：

Ueda K. ^{[1
]}

Suekane S. ^{[1
]}

Ogasawara N. ^{[1
]}

Chikui K. ^{[1
]}

Suyama S. ^{[1
]}

Nakiri M. ^{[1
]}

Nishihara K. ^{[1
]}

Matsuo M. ^{[1
]}

Igawa T. ^{[1
]}

机构：

[1] Department of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume

来源：

Journal of Medical Case Reports | / 10卷 / 1期

关键词：

Long-term response; Monotherapy; Renal cell carcinoma; Sorafenib;

D O I：

10.1186/s13256-016-0961-0

中图分类号：

学科分类号：

摘要：

Background: Molecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. However, patients in whom the treatment could initially be effective will experience disease progression later. Case presentation: A 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction, occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe adverse events. Conclusions: We present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10 years while receiving sorafenib monotherapy. © 2016 The Author(s).

引用

共 25 条

[1]

Chow W.H., Devesa S.S., Warren J.L., Fraumeni J.F., Rising incidence of renal cell cancer in the United States, JAMA, 281, pp. 1628-1631, (1999)

[2]

Motzer R.J., Bander N.H., Nanus D.M., Renal-cell carcinoma, N Engl J Med, 335, pp. 865-875, (1996)

[3]

Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Et al., Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, pp. 125-134, (2007)

[4]

Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, pp. 2271-2281, (2007)

[5]

Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, pp. 115-124, (2007)

[6]

Rini B.I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T.E., Et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial, Lancet, 378, pp. 1931-1939, (2011)

[7]

Yasuda Y., Saito K., Yuasa T., Kitsukawa S., Urakami S., Yamamoto S., Et al., Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors, Int J Clin Oncol, 18, pp. 884-889, (2013)

[8]

Patil S., Figlin R.A., Hutson T.E., Michaelson M.D., Negrier S., Kim S.T., Et al., Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma, Ann Oncol, 22, pp. 295-300, (2011)

[9]

Beuselinck B., Oudard S., Rixe O., Wolter P., Blesius A., Ayllon J., Et al., Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib, Ann Oncol, 22, pp. 794-800, (2011)

[10]

Seidel C., Busch J., Weikert S., Steffens S., Bokemeyer C., Grunwald V., Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC), Br J Cancer, 109, pp. 2998-3004, (2013)

← 1 2 3 →